Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell therapy in ...
Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet cell therapy appears to be paying off so far. The allogeneic human stem ...
Trial results could underpin request for regulatory approval Bayer already working on manufacturing network Several other research teams working on similar treatments SAN SEBASTIAN, Spain, Sept 22 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback